Primary information |
---|
sequence ID | Seq_1526 |
Peptide sequence | DSGEGDFLAEGGGVR |
CancerPDF_ID | CancerPDF_ID8, CancerPDF_ID637, CancerPDF_ID1026, CancerPDF_ID1217, CancerPDF_ID2313, CancerPDF_ID8502, CancerPDF_ID9674, CancerPDF_ID10143, CancerPDF_ID11071, CancerPDF_ID11394, CancerPDF_ID12678, |
PMID | 16896061,19795908,16395409,21136997,21136997,23667664,21533267,21805675,27043541,26992070,25168216 |
Protein Name | Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinopeptide A,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha chain |
UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
Fluid | Serum,Plasma,Serum,Serum,Plasma,Serum,Serum,Urine,Serum,Serum,Serum |
M/Z | 1465.65,733.33,1465.65,1464.6481,1464.6481,1464.65,733.31,1465.6552,1545.6249,NA,NA |
Charge | 1,2,1,1,1,1,2,NA,NA,NA,NA |
Mass (in Da) | 1465.65,NA,NA,NA,NA,1466.5,NA,NA,NA,1465.655565,NA |
fdr | NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1464.65 |
Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,LC-MS,MALDI-TOF,MALDI-TOF,LC-MS,LC-MS |
Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,MALDI-TOF-MS,LC-MALDI-TOF/TOF-MS/MS,LC-MS/MS,LC-MS/MS |
Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,NA,Multiple Reaction Monitoring,NA,NA,NA,NA |
Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
FDR | NA,less than 7%,less than 1 “5,NA,0.001,NA,1.49,1,NA,FDR 1 %,NA |
CancerPDF_ID | CancerPDF_ID8, CancerPDF_ID637, CancerPDF_ID1026, CancerPDF_ID1217, CancerPDF_ID2313, CancerPDF_ID8502, CancerPDF_ID9674, CancerPDF_ID10143, CancerPDF_ID11071, CancerPDF_ID11394, CancerPDF_ID12678, |
p-Value | 1.00E-05,NA,1.88E-07,7.57E-05,7.57E-05,NA,3.80E-15,NA,NA,NA,3.76E_04 |
Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT,NA,MASCOT,SEQUEST and Maxquant,MASCOT |
Length | 15,15,15,15,15,15,15,15,15,15,15 |
Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Muscle-invasive bladder cancer,Non-small cell lung cancer (NSCLC),Melanoma,Renal cell carcinaoma |
Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,NA,Swissprot Database (57.4),SwissProt Database,SwissProt Database,SwissProt Database,SwissProt Database |
Modification | NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA |
Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,27 healthy individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,751 bladder cancer and 127 control,477 patients and healthy controls,8 cancer samples and 4 healthy samples,"30 RCC patients and 30 healthy controls for training dataset and 6 RCC patients, 6 control in independent validation dataset" |
Regulation | Differentially expressed between cancer vs normal samples,NA,"Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.66, 0.55 and 0.8 in prostate, bladder and breast cancer respectively",Differentially expressed between cancer vs normal,Differentially expressed between cancer vs normal,NA,Differentially expressed between Lung cancer vs control,Differentially expressed between cancer vs normal samples,Differentially expressed between cancer vs normal,"Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples.",Upregulated in cancer v/s Normal |
Validation | Independent validation,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,NA,MRM-based validation of 19 candidates,Mann-Whitney tests and areas under receiver-operator characteristic,external cross validation done,na,Independent validation |
Sensitivity | 95% on independent dataset,NA,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,0.898,0.898,NA,NA,NA,NA,NA,100 % (for 19 peptide signatures) |
Specificity | 95% on independent dataset,NA,NA,0.946,0.946,NA,NA,NA,NA,NA,NA |
Accuracy | NA,NA,97.5 % on validation dataset,NA,0.917,NA,0.805,NA,NA,NA,AUC : 0.858 |
Peptide Atlas | PeptideAtlas |
IEDB | 462581
|